{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon+and+Ribavirin", "query": { "intervention": "Pegylated Interferon and Ribavirin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 124, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon+and+Ribavirin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T04:29:32.545Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01872936", "title": "Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Miravirsen", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santaris Pharma A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2013-06", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01872936" }, { "nct_id": "NCT01384383", "title": "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 248, "start_date": "2011-08", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384383" }, { "nct_id": "NCT01405027", "title": "Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C", "Genotype 1" ], "interventions": [ { "name": "Educational Intervention", "type": "PROCEDURE" }, { "name": "Patient education and management skills training", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Chronic Liver Disease Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2011-12", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 43, "location_summary": "Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Calabasas", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405027" }, { "nct_id": "NCT01459913", "title": "Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 239, "start_date": "2011-11", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-06-10", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01459913" }, { "nct_id": "NCT00056862", "title": "Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2003-03", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-12-06", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056862" }, { "nct_id": "NCT01054573", "title": "VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "pegylated interferon (Peg-IFN) alfa-2a", "type": "DRUG" }, { "name": "ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Infectious Diseases BVBA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2010-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-05-08", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 14, "location_summary": "Coronado, California • Los Angeles, California • San Francisco, California + 11 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054573" }, { "nct_id": "NCT01297270", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 658, "start_date": "2011-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-09-18", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297270" }, { "nct_id": "NCT03067129", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatitis C Virus (HCV)" ], "interventions": [ { "name": "Glecaprevir/Pibrentasvir Adult Formulation", "type": "DRUG" }, { "name": "Glecaprevir + Pibrentasvir Pediatric Formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 129, "start_date": "2017-03-20", "completion_date": "2022-09-12", "has_results": true, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 15, "location_summary": "San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03067129" }, { "nct_id": "NCT01482390", "title": "A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Mericitabine", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-11-30", "completion_date": "2014-01-31", "has_results": false, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482390" }, { "nct_id": "NCT00487318", "title": "Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "standard of care", "type": "DRUG" }, { "name": "fluvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bader, Ted, M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2007-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2012-08-21", "last_synced_at": "2026-10-06T04:29:32.545Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487318" } ] }